2026-04-17T18:59:53Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/69212025-10-24T10:26:05Zcom_2072_378070com_2072_378040col_2072_378092

Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation Tao, Weiyang Lacna, Amelia van Veghel, Karin Horwitz, Mitchell E. Sanz, Guillermo Valcarcel Ferreiras, David de Koning, Coco Institut Català de la Salut [de Koning C] University Medical Center Utrecht, Utrecht, The Netherlands. Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. [Tao W, Lacna A, van Veghel K] University Medical Center Utrecht, Utrecht, The Netherlands. [Horwitz ME] Duke University Medical Center, Durham, NC, USA. [Sanz G] Hospital Universitario y Politécnico la Fe, València, Spain. Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Instituto de Salud Carlos III, Madrid, Spain. [Valcárcel D] Vall d’Hebron Hospital Universitari, Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Trasplantació d'òrgans, teixits, etc. Sang fetal Sang - Malalties - Tractament ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Cell- and Tissue-Based Therapy::Cell Transplantation::Stem Cell Transplantation::Cord Blood Stem Cell Transplantation DISEASES::Neoplasms::Neoplasms by Site::Hematologic Neoplasms Other subheadings::Other subheadings::/therapy TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::tratamientos basados en células y tejidos::trasplante de células::trasplante de células madre::trasplante de células madre de la sangre del cordón ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias hematológicas Otros calificadores::Otros calificadores::/terapia Immunologia; Recerca mèdica Inmunología; Investigación médica Immunology; Medical research Omidubicel (nicotinamide-expanded cord blood) is a potential alternative source for allogeneic hematopoietic cell transplantation (HCT) when an HLA-identical donor is lacking. A phase I/II trial with standalone omidubicel HCT showed rapid and robust neutrophil and platelet engraftment. In this study, we evaluated the immune reconstitution (IR) of patients receiving omidubicel grafts during the first 6 months post-transplant, as IR is critical for favorable outcomes of the procedure. Data was collected from the omidubicel phase I-II international, multicenter trial. The primary endpoint was the probability of achieving adequate CD4+ T-cell IR (CD4IR: > 50 × 106/L within 100 days). Secondary endpoints were the recovery of T-cells, natural killer (NK)-cells, B-cells, dendritic cells (DC), and monocytes as determined with multicolor flow cytometry. LOESS-regression curves and cumulative incidence plots were used for data description. Thirty-six omidubicel recipients (median 44; 13–63 years) were included, and IR data was available from 28 recipients. Of these patients, 90% achieved adequate CD4IR. Overall, IR was complete and consisted of T-cell, monocyte, DC, and notably fast NK- and B-cell reconstitution, compared to conventional grafts. Our data show that transplantation of adolescent and adult patients with omidubicel results in full and broad IR, which is comparable with IR after HCT with conventional graft sources. 2022-01-28T06:53:46Z 2022-01-28T06:53:46Z 2021-11 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion de Koning C, Tao W, Lacna A, van Veghel K, Horwitz ME, Sanz G, et al. Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation. Bone Marrow Transplant. 2021 Nov;56:2826–2833. 1476-5365 https://hdl.handle.net/11351/6921 10.1038/s41409-021-01417-4 34312498 000679018100001 http://hdl.handle.net/11351/6921 eng Bone Marrow Transplantation;56 https://doi.org/10.1038/s41409-021-01417-4 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess application/pdf application/pdf Springer Nature Scientia